Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,127JPY
9:10pm EDT
Change (% chg)

¥-140 (-2.66%)
Prev Close
¥5,267
Open
¥5,177
Day's High
¥5,179
Day's Low
¥5,123
Volume
996,400
Avg. Vol
2,163,135
52-wk High
¥5,527
52-wk Low
¥4,098

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical says PRA Health Sciences and Takeda Partnership Expands to Japan
Wednesday, 15 Feb 2017 02:00am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Says PRA Health Sciences Inc and Takeda Pharmaceutical Company Limited have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan . Says Takeda and PRA will establish a joint venture, each holding 50 percent of the share respectively, to provide clinical trial delivery and pharmacovigilance services as a strategic partner of Takeda in Japan. .Says Takeda also will transfer all of the shares of Takeda Pharmaceutical Data Services (TDS), a wholly-owned subsidiary of Takeda, to PRA.  Full Article

Tigenix announces positive results of ADMIRE-CD pivotal phase III trial of Cx601
Monday, 6 Feb 2017 01:30am EST 

Tigenix NV : Announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO . Positive results of ADMIRE-CD pivotal phase III trial of Cx601 for complex perianal fistulas in Crohn's disease patients . Data demonstrated that remission produced in these hard-to-treat fistulas by Cx601, a suspension of allogeneic adipose-derived stem cells (eASC), was maintained long-term . Results also support favorable tolerability of Cx601 over long-term - Dr. Marie Paule Richard, Chief Medical Officer at Tigenix .Has an exclusive licensing and commercialization agreement for Cx601, ex-US, with Takeda <4502.T> and expects a decision from the EMA regarding its marketing authorization by year-end 2017.  Full Article

Takeda Pharmaceutical to raise up to T$35 mln via private placement
Thursday, 6 Oct 2016 07:12am EDT 

Takeda Pharmaceutical Co Ltd <4502.T>:Says it to issue up to 3,500,000 shares via private placement and to raise up to totally T$35 million.  Full Article

Takeda Pharmaceutical to expand into sub-Saharan Africa - Nikkei<4502.T>
Thursday, 25 Aug 2016 03:17pm EDT 

Nikkei : Takeda Pharmaceutical will expand into sub-Saharan Africa with operations set to reach full swing in next two-to-three years .  Full Article

Ultragenyx files for resale of upto 374,590 shares of co
Wednesday, 10 Aug 2016 06:05pm EDT 

Ultragenyx Pharmaceutical :Files for resale of upto 374,590 shares of co by Takeda Pharma Co ltd/its pledgees, assignees/successor-in-interest.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 06:59am EDT 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Fujifilm to bid for Takeda's research reagents unit - Nikkei
Thursday, 21 Jul 2016 01:18pm EDT 

: Fujifilm Holdings is set to make an offer for a laboratory chemicals unit of Takeda Pharmaceutical - Nikkei . Takeda is expected to put Wako Pure Chemical Industries on the chopping block as early as August - Nikkei .Among those interested in Wako Pure Chemical Business are Britain's Permira and other equity funds, as well as a major U.S. medical supplies Co - Nikkei.  Full Article

Takeda working with Nomura Holdings to sell chemicals unit - Bloomberg
Thursday, 21 Jul 2016 10:45am EDT 

:Takeda working with Nomura Holdings to sell chemicals unit, which could fetch more than $1 billion - Bloomberg, citing sources.  Full Article

TiGenix and Takeda enter into licensing agreement for ex-U.S. Rights to CX601
Tuesday, 5 Jul 2016 02:06am EDT 

TiGenix NV : Takeda <4502.T> and TiGenix enter into licensing agreement for ex-u.s. Rights to CX601 for treatment of complex perianal fistulas in patients with crohn's disease . TiGenix will receive an upfront cash payment of 25 million euros ($27.8 million) . TiGenix will be eligible to receive additional regulatory and sales milestone payments for up to a potential total of 355 million euros and double digit royalties on net sales by Takeda . First anticipated milestone payment is 15 million euros upon obtaining marketing authorization of CX601 in European Economic Area (EEA) .In addition, takeda will make an equity investment of 10 million euros in share capital of Tigenix within next 12 months.  Full Article

Takeda Pharmaceutical, Altos Therapeutics to develop Altos's ATC-1906
Friday, 1 Jul 2016 08:00am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Co, Altos Therapeutics have entered into agreement to further development of Altos's proprietary compound ATC-1906 . Deal has option for co to acquire Altos from date of agreement, continuing for some time after completion of Phase 1 studies of ATC-1906 . As part of agreement, Takeda will provide Altos an upfront payment for option to acquire Altos . If Takeda elects to exercise option to buy Altos, Takeda would make an additional payment to acquire Altos . Altos would be eligible to receive additional payments linked to clinical development and achievement of key commercial milestones .No further details of agreement were disclosed.  Full Article

More From Around the Web

BRIEF-Takeda Pharmaceutical forms drug development company with two partners - Nikkei

* Takeda pharmaceutical formed 10 billion yen ($87.2 million) drug development company with two partners